Robert F. Kennedy Jr. Nominated for HHS

President-elect Donald Trump has nominated Robert F. Kennedy Jr. for Secretary of Health and Human Services, sparking controversy due to Kennedy's skepticism regarding vaccines and other health issues. A coalition of health advocates, including Protect Our Care, has launched a campaign against his nomination, citing concerns over his stances on public health. Conversely, a letter from 800 medical professionals endorsing Kennedy emphasizes a need for systemic reforms to address America's declining health outcomes. Meanwhile, Novo Nordisk's diabetes drug Ozempic is under scrutiny for links to a rare eye condition, and the company is also investing in a facility for rare disease drugs. Critics argue that Kennedy’s appointment might exacerbate health issues, while some believe it could ignite necessary discussions on chronic disease management. The divergent views showcase the complexities surrounding Kennedy's potential role in public health.